CRISPR/cas9 genome editing is used to insert an in-frame T2A ribosome skipping sequence and Cre recombinase/ERT2 fusion immediately following the final M366 residue in exon 7. The inserted sequence is not expected to affect expression of Dcx. (J:343514)